Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

GLP-1 agonists

This page shows the latest GLP-1 agonists news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk gets FDA okay for new diabetes hope

Novo Nordisk gets FDA okay for new diabetes hope

Potential to combat increasing competition and pricing pressures. Novo Nordisk has FDA approval for the first oral alternative to injectable GLP-1 agonists, which the company thinks could be a blockbuster ... product. The US regulator has approved the

Latest news

  • Novo Nordisk shareholder revolt reaches Europe Novo Nordisk shareholder revolt reaches Europe

    Novo Nordisk has latterly become less reliant on sales of its insulin products as newer products, particularly GLP-1 agonists Victoza (liraglutide) and Ozempic (semaglutide), have increased their share of revenues.

  • Lilly’s Trulicity cuts heart and kidney risks in diabetes by 12% Lilly’s Trulicity cuts heart and kidney risks in diabetes by 12%

    Lilly revealed last November that the top-line data with the once-weekly GLP-1 agonist was positive, and over the weekend at the American Diabetes Association meeting, presented the detailed ... Trulicity's growth to date has stemmed largely from its once

  • Novo's semaglutide beats Lilly's Trulicity in diabetes contest Novo's semaglutide beats Lilly's Trulicity in diabetes contest

    Novo Nordisk says its once-weekly GLP-1 agonist semaglutide could become a "new standard" in type 2 diabetes after beating rival Eli Lilly's Trulicity (dulaglutide) in a phase III ... Trulicity's growth stems from its once-weekly dosing, which has proved

  • Sanofi's lixisenatide is back under FDA review Sanofi's lixisenatide is back under FDA review

    In the interim Novo Nordisk's rival Victoza (liraglutide) has firmly established itself at the top of the GLP-1 agonist tree, with sales of around $2bn a year. ... Meanwhile, new GLP-1 agonists that require dosing just once a week - including Eli Lilly's

  • Sanofi plans LixiLan filings after positive phase III trial Sanofi plans LixiLan filings after positive phase III trial

    If approved it will compete in the market with Novo Nordisk's insulin/GLP-1 agonist product Xultophy (insulin degludec/liraglutide), which was launched earlier this year. ... Jefferies' Peter Wellford indicating earlier this year that the basal

More from news
Approximately 8 fully matching, plus 37 partially matching documents found.

Latest Intelligence

  • Deal Watch table for January 2015 Deal Watch table for January 2015

    Licence collaboration agreement. 1, 110. Janssen/ Depomed. Nucynta [tapentadol] franchise including extended release tablets and oral solutions. ... Asset acquisition. 142.  Amunix/Naia. To develop glucagon peptide agonists GLP-1-XTEN and GLP-2-XTEN in

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

PANDAS/PANS Awareness: A parent’s story
To help raise awareness of these often underdiagnosed diseases, Jon Hallows, Joint MD at Porterhouse shares his own experience as a parent of a son recently diagnosed with PANDAS...
Iskra Reic
Leading AstraZeneca’s return to growth in Europe
PME talks to Iskra Reic, the company’s head of Europe and Canada...
The era of digital wellbeing
Social media - friend or foe?...

Quick links

Infographics

Multimedia